Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Apr 28;94(8):1327–1336. doi: 10.1007/s00277-015-2383-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2015

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Fig. 1 — Treatment schedule of AML-BFM 98 and AML-BFM 04 studies for high-risk patients. AIE cytarabine/idarubicin/etoposide; ADxE cytarabine/l-daunorubicin/etoposide; HAM high-dose cytarabine (3 g/m2 q12h over 3 days)/mitoxantrone; AI cytarabine/idarubicin; AI/2-CDA cytarabine/idarubicin/2-chloro-2-deoxyadenosine; haM high-dose cytarabine (1 g/m2 q12h over 3 days)/mitoxantrone; consolidation 6-thioguanine/prednisone/vincristine/idarubicin/cytarabine/cyclophosphamide; HAE high-dose cytarabine (3 g/m2 q12h over 3 days)/ etoposide; MSD matched sibling donor; asterisk indicates until 2006; CNS irradiation; maintenance 12 months thioguanine/cytarabine; R1 first random assignment; R2 second random assignment; R3 third random assignment